[go: up one dir, main page]

PE20181074A1 - Compuestos heteroaromaticos como inhibidores de btk - Google Patents

Compuestos heteroaromaticos como inhibidores de btk

Info

Publication number
PE20181074A1
PE20181074A1 PE2018001111A PE2018001111A PE20181074A1 PE 20181074 A1 PE20181074 A1 PE 20181074A1 PE 2018001111 A PE2018001111 A PE 2018001111A PE 2018001111 A PE2018001111 A PE 2018001111A PE 20181074 A1 PE20181074 A1 PE 20181074A1
Authority
PE
Peru
Prior art keywords
heteroaromatic compounds
btk inhibitors
pyridinyl
halo
halogen
Prior art date
Application number
PE2018001111A
Other languages
English (en)
Inventor
Todd Bosanac
Joerg Bentzien
Michael Jason Burke
Ryan Michael Fryer
Eric Thomas Larson
Wang Mao
Bryan Patrick Mckibben
Yue Shen
Fariba Soleymanzadeh
Matt Aaron Tschantz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20181074A1 publication Critical patent/PE20181074A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion refiere un compuesto de formula (I) donde Cy se selecciona de i, ii, cada R1 es H o metilo; R2 es L-Ar en donde Ar es fenilo o piridinilo, y cada uno se sustituye opcionalmente con uno o mas de halogeno, halo C1-C4, entre otros; L es -(CH2)-; Y es C6-C8 espirociclo que contiene 1 atomo de nitrogeno del anillo. Tambien refiere una composicion farmaceutica y es util para el tratamiento de artritis reumatoide, nefritis lupica, rinitis alergica, entre otros mencionados en la invencion.
PE2018001111A 2015-12-16 2016-12-15 Compuestos heteroaromaticos como inhibidores de btk PE20181074A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268278P 2015-12-16 2015-12-16
US201662431008P 2016-12-07 2016-12-07

Publications (1)

Publication Number Publication Date
PE20181074A1 true PE20181074A1 (es) 2018-07-04

Family

ID=58737849

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001111A PE20181074A1 (es) 2015-12-16 2016-12-15 Compuestos heteroaromaticos como inhibidores de btk

Country Status (30)

Country Link
US (6) US9975882B2 (es)
EP (1) EP3390390B1 (es)
JP (1) JP6976947B2 (es)
KR (1) KR102691112B1 (es)
CN (1) CN108368086B (es)
AU (1) AU2016370743B2 (es)
BR (1) BR112018011969B1 (es)
CA (1) CA3005268C (es)
CL (1) CL2018001569A1 (es)
CO (1) CO2018005954A2 (es)
CY (1) CY1124749T1 (es)
DK (1) DK3390390T3 (es)
EA (1) EA034561B1 (es)
ES (1) ES2897910T3 (es)
HR (1) HRP20211845T1 (es)
HU (1) HUE056877T2 (es)
IL (1) IL259281B (es)
LT (1) LT3390390T (es)
MX (1) MX375471B (es)
MY (1) MY197440A (es)
PE (1) PE20181074A1 (es)
PH (1) PH12018501248B1 (es)
PL (1) PL3390390T3 (es)
PT (1) PT3390390T (es)
RS (1) RS62525B1 (es)
SA (1) SA518391864B1 (es)
SG (1) SG11201804890TA (es)
SI (1) SI3390390T1 (es)
TW (1) TWI726017B (es)
WO (1) WO2017106429A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013299557B2 (en) 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
UA122258C2 (uk) 2015-12-16 2020-10-12 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази
BR112018011969B1 (pt) * 2015-12-16 2023-02-23 Boehringer Ingelheim International Gmbh Compostos heteroaromáticos como inibidores de btk, seu uso, seu processo para preparação e composição farmacêutica que os compreende
JP6916185B2 (ja) 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としてのイソキノロン類
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
CN110944999A (zh) * 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
CA3224949A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
HUE060872T2 (hu) * 2018-12-03 2023-04-28 Boehringer Ingelheim Int Heteroaromás vegyületek mint vanin-inhibitorok
ES3026660T3 (en) * 2018-12-03 2025-06-11 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
US12383556B2 (en) * 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
JP4739632B2 (ja) * 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Erkのインヒビターとして有用なピラゾール組成物
NZ530772A (en) 2001-08-13 2006-03-31 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
AU2002366440A1 (en) 2001-09-27 2003-09-09 Smithkline Beecham Corporation Chemical compounds
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
ATE534632T1 (de) 2006-04-11 2011-12-15 Vertex Pharma Thiazole, imidazole und pyrazole als proteinkinasehemmer
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
DK2310528T3 (da) 2008-07-29 2013-12-02 Univ Liege Genetisk markør-test til brachyspina og frugtbarhed hos kvæg
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
EP2513066A1 (de) 2009-12-17 2012-10-24 Merck Patent GmbH Inhibitoren der sphingosinkinase
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2863239C (en) * 2012-01-31 2016-09-13 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
AU2013299557B2 (en) 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
EP2914586B1 (en) 2012-11-02 2017-04-05 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8895750B2 (en) * 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としてのピラゾール化合物
BR112018011969B1 (pt) * 2015-12-16 2023-02-23 Boehringer Ingelheim International Gmbh Compostos heteroaromáticos como inibidores de btk, seu uso, seu processo para preparação e composição farmacêutica que os compreende

Also Published As

Publication number Publication date
RS62525B1 (sr) 2021-11-30
JP2019505491A (ja) 2019-02-28
LT3390390T (lt) 2021-11-25
SG11201804890TA (en) 2018-07-30
US9975882B2 (en) 2018-05-22
IL259281B (en) 2021-04-29
US20170174663A1 (en) 2017-06-22
BR112018011969B1 (pt) 2023-02-23
US20180030037A1 (en) 2018-02-01
DK3390390T3 (da) 2021-12-06
US20200055843A1 (en) 2020-02-20
TW201731838A (zh) 2017-09-16
EA201891399A1 (ru) 2019-01-31
US20190092759A1 (en) 2019-03-28
PH12018501248A1 (en) 2019-01-28
MX375471B (es) 2025-03-06
EP3390390B1 (en) 2021-09-01
SI3390390T1 (sl) 2021-12-31
CY1124749T1 (el) 2022-07-22
US20210009567A1 (en) 2021-01-14
AU2016370743A1 (en) 2018-05-24
CO2018005954A2 (es) 2018-07-10
MX2018007333A (es) 2018-08-24
CA3005268C (en) 2024-04-30
AU2016370743B2 (en) 2020-11-26
HRP20211845T1 (hr) 2022-03-04
PL3390390T3 (pl) 2022-01-24
BR112018011969A2 (pt) 2018-12-04
US20180222893A1 (en) 2018-08-09
HK1256795A1 (en) 2019-10-04
IL259281A (en) 2018-07-31
PT3390390T (pt) 2021-11-18
CN108368086A (zh) 2018-08-03
WO2017106429A3 (en) 2017-08-17
ES2897910T3 (es) 2022-03-03
KR102691112B1 (ko) 2024-08-05
KR20180095655A (ko) 2018-08-27
WO2017106429A2 (en) 2017-06-22
JP6976947B2 (ja) 2021-12-08
CA3005268A1 (en) 2017-06-22
EA034561B1 (ru) 2020-02-20
SA518391864B1 (ar) 2021-12-13
TWI726017B (zh) 2021-05-01
PH12018501248B1 (en) 2023-03-10
MY197440A (en) 2023-06-19
HUE056877T2 (hu) 2022-03-28
CL2018001569A1 (es) 2018-10-05
EP3390390A2 (en) 2018-10-24
CN108368086B (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
EA202091484A1 (ru) 4-азаиндольные соединения
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201791304A1 (ru) Производные изохинолина для лечения вич
PE20190711A1 (es) N-(fenils ulfonil) benzamidas y compuestos relacionados como inhibidores de bcl-2
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
EA201891644A1 (ru) Антибактериальные соединения и их применение
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20161407A1 (es) Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide